Mucommune is a research and development organization specializing in immunology, drug delivery, and mucosal biology. The company focuses on advancing early-stage academic discoveries into preclinical studies and clinical development. Among its notable technologies are innovative monoclonal antibody (mAb) therapies targeting acute respiratory infections and first-in-class interventions for female reproductive health. Mucommune's proprietary platforms leverage the synergy between antibodies and mucus to enhance mucosal health, enabling the development of drug delivery systems such as on-demand vaginal tablets and sustained-release intravaginal rings. These technologies aim to address unmet needs in female reproductive health with a focus on safety, potency, and user-friendliness.

Additionally, Mucommune is advancing technologies through its subsidiary, Polyon Pharmaceuticals, which specializes in addressing the immunogenicity of polyethylene glycol (PEG) in therapeutics. Polyon's patented formulation approach aims to reduce the induction of anti-PEG antibodies, thereby enhancing the efficacy and safety of PEGylated drugs. This molecularly specific intervention has shown promise in preclinical studies, offering a potential solution to hypersensitivity reactions associated with PEG-modified therapeutics. Overall, Mucommune's expertise and innovative platforms position it at the forefront of developing advanced therapeutic solutions in immunology and drug delivery.

United States

First in-class platform for harnessing the synergy between antibodies and mucus to reinforce the mucus barrier for mucosal health Proprietary intravaginal ring technologies for sustained delivery of small molecules to biomacromolecules Unparalleled safety from topical delivery

Mucommune

Company Details